Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas.

Japanese journal of clinical oncology - 1 Feb 1997

Asamoto M, Iwahori Y, Okamura T, Shirai T, Tsuda H

Abstract excerpt

The p16 (CDKN2,MTS1) gene is located at 9p21 and its product, p16, inhibits the cyclin D/CDK4 complex. Loss of heterozygosity on chromosome 9p is very common in human bladder carcinomas and has been found in all stages of lesions, suggesting that it occurs early in bladder tumor progression. Several studies have revealed frequent homozygous deletion of the p16 gene in cell lines, and that such deletions are also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carrier Proteins
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Primers

Share to Gene Expression

Share to Mutation

Share to Polymerase Chain Reaction

Share to Polymorphism, Single-Stranded Conformational

Share to RNA, Messenger

Source

Identifiers

PMID: 9070336
DOI: 10.1093/jjco/27.1.22

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas.PMID 9070336Read ↗

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.Semantic proximity Read ↗

Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.Semantic proximity Read ↗

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer.Semantic proximity Read ↗

Deletion of the p16 and p15 Genes in Human Bladder TumorsSemantic proximity Read ↗

Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.Semantic proximity Read ↗

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.Semantic proximity Read ↗

Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.Semantic proximity Read ↗

Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.Semantic proximity Read ↗

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.Semantic proximity Read ↗

Bladder cancer. I. Molecular and genetic basis of carcinogenesis.Semantic proximity Read ↗

Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.Semantic proximity Read ↗

No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.